VFL Sciences partners with Cytosurge AG to bring FluidFM® OMNIUM platform to India

VFL Sciences has entered a partnership with Cytosurge AG to offer the FluidFM® OMNIUM platform, a semi-automated single-cell manipulation system for non-destructive injection and extraction, compatible with single-cell RNA analysis and advanced gene editing techniques. With the blend of its products and partnered products, VFL Sciences has positioned itself as a complete solution provider for several workflows in life science laboratories.

Dr. Magid Haddouchi, Chief Commercial Officer at Cytosurge, states:

“India is one of the fastest-growing markets for scientific instruments, and we are excited to cooperate with VFL Sciences to grow our business further. With their experienced team, VFL Sciences will be your go-to partner for FluidFM OMNIUM expertise, support, and solutions, especially within Pharma, Biopharma, and Cell and Gene Therapy laboratories across India.”

Vancheeswaran Sankaranarayanan, Managing Director of VFL Sciences, emphasized:

“Our collaboration with Cytosurge brings Indian researchers access to world-leading single-cell analysis technology. We strongly believe that FluidFM technology’s global reputation in single-cell analysis will enable us to offer our customers the best solutions for their research, helping them gain deeper insights into cellular behavior, improve experimental accuracy, and accelerate innovation across the life sciences.”

About VFL Sciences:
At VFL Sciences, our core focus is on providing advanced instruments, consumables, and reagents for scientific studies, dedicated to creating a positive global impact. As an embodiment of ‘Voice for Local,’ we actively support Indian science by offering cutting-edge products and services that seamlessly blend the finest imported and Indian technologies. Our goal is to contribute towards making the world a better place to live in.

About Cytosurge AG:
Cytosurge is a synthetic biology enabler specialized in its proprietary FluidFM® technology for precise single-cell manipulation, with 140+ systems installed globally and 150+ publications since 2009.

FluidFM OMNIUM Platform: A semi-automated system for non-destructive single-cell injections and extractions, enabling low-input RNA sequencing while keeping cells alive and advanced gene editing workflows.
CellEDIT Service: Powered by FluidFM, delivers precise gene edits via gentle intra-nuclear CRISPR RNP injections, minimizing stress and off-target effects, ideal for hard-to-transfect cells.

Learn more at www.cytosurge.com and follow us on X, Bluesky, LinkedIn, and Facebook.